查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1942489

2026年全球乳癌诊断市场报告

Breast Cancer Diagnostics Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，乳癌诊断市场成长显着，预计到2025年将达到50亿美元，到2026年将达到54.2亿美元，复合年增长率为8.3%。过去几年的成长可归因于多种因素，例如全球乳癌率的上升、早期癌症筛检意识提升、诊断影像基础设施的扩展、生物标记检测的日益普及以及切片检查准确性和安全性的提高。

预计未来几年乳癌诊断市场规模将强劲成长，2030年将达到72.8亿美元，复合年增长率（CAGR）为7.7%。预测期内的成长可归因于精准肿瘤诊断技术的日益普及、人工智慧诊断平台投资的增加、对微创检测需求的增长、基于人群的筛检项目的扩展以及分子诊断技术的持续进步。预测期内的关键趋势包括人工智慧辅助影像分析的日益普及、基因组和分子检测的广泛应用、液态生物检体技术的日益普及、先进的非电离辐射成像方式的扩展以及对早期和个性化诊断的日益重视。

乳癌诊断市场は今后数年间、政府主导の乳癌対策および资金支援により成长が见込まれます。こうした施策は公众卫生と経済発展に寄与するプログラムや计划への财政的支援を提供します。これらの取り组みは、启発活动の推进、検诊や乳房X光摄影による早期発见の促进、医疗サービスが行き届いていない地域への検査・治疗费の财政的支援を通じて、乳癌の研究・予防・治疗を支える重要な役割を果たしています。例えば、オーストラリア卫生署は2022-23年度予算において、各种がん検査・筛检サービスのアクセス改善、COVID-19パンデミックによる遅延の解消、适切な绍介・迅速な诊断・早期疗育の実现に向け、4,070万豪ドルを配分しました。このうち970万豪ドルは乳癌検诊に特化して充てられています。したがって、政府の取り组みと资金提供が乳癌诊断市场の拡大を支えているのです。

乳癌诊断市场的主要企业正致力于人工智慧驱动的创新，旨在提高诊断准确性、简化工作流程并支援个人化治疗方案。基于人工智慧的诊断平台利用机器学习和深度学习演算法分析医学影像、病理切片和临床数据，从而提供洞察和风险分层，为临床决策提供支援。例如，2024年9月，以色列数位病理公司Ibex Medical Analytics扩展了其乳癌诊断人工智慧平台，在其Ibex Breast HER2模组中引入了全自动、零点击的HER2免疫组化（IHC）评分功能。该工具能够识别浸润性癌症区域并对HER2表达水平（0、1+、2+、3+）进行分类，以更高的准确性和工作流程效率支持乳癌的诊断和治疗决策。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 世界の乳癌诊断市场：魅力度スコアと分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 人工智慧（AI）和自主人工智慧
    • 生物技术、基因组学和精准医学
    • 数位化、云端运算、巨量资料、网路安全
    • 物联网、智慧基础设施和互联生态系统
    • 工业4.0和智慧製造
  • 主要趋势
    • 人工智慧辅助影像分析的应用日益广泛
    • ゲノム検査および分子検査の利用拡大
    • 液态生物检体技术的应用日益广泛
    • 扩展先进的非电离辐射成像方法
    • 越来越重视早期和个人化诊断

第五章 终端用户产业市场分析

  • 医院和诊所
  • 诊断检查室
  • 癌症研究中心
  • 门诊手术中心
  • 专科肿瘤诊所

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球乳癌诊断市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 世界の乳癌诊断市场规模、比较、成长率分析
  • 全球乳癌诊断市场表现：规模与成长，2020-2025年
  • 世界の乳癌诊断市场の予测：规模と成长、2025年～2030年、2035年

第八章 全球潜在市场规模（TAM）

第九章 市场细分

  • 按类型
  • 画像诊断、切片检查、ゲノム検査、血液検査、その他のタイプ
  • 透过技术
  • 萤光in situ杂合反应（FISH）、比较ゲノム杂合反应（CGH）、免疫组织化学（IHC）、その他の技术
  • 按癌症类型
  • BRCA乳癌、ERおよびPR乳癌、HER2阳性乳癌、トリプルネガティブ乳癌、その他のがんタイプ
  • 按诊断类型
  • 利用电离辐射的乳房摄影诊断技术，利用非电离辐射的影像诊断技术
  • 最终用户
  • 病院および诊疗所、がん研究センター、诊断检查室、外来手术センター
  • 按类型细分：诊断成像
  • 乳房超音波影像摄影、超音波影像、磁振造影（MRI）、正子断层扫描（PET）、断层合成影像
  • 按类型细分：切片检查
  • 针吸切片、粗针穿刺切片、细针穿刺切片检查（FNA）、立体定位切片检查
  • 按类型细分：基因组检测
  • Oncotype DX、MammaPrint、PAM50、BRCA1 或 BRCA2 检测
  • 按类型细分：血液检测
  • 液态生物检体、循环肿瘤DNA（ctDNA）检测、循环性肿瘤细胞（CTC）检测
  • 按类型细分：其他类型
  • 荷尔蒙受体检测、HER2检测、基因突变检测

第十章 区域与国家分析

  • 世界の乳癌诊断市场：地域别、実绩と予测、2020年～2025年、2025年～2030年、2035年
  • 世界の乳癌诊断市场：国别、実绩と予测、2020年～2025年、2025年～2030年、2035年

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第二十章：西欧市场

第21章英国市场

第22章 德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章 东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第30章：加拿大市场

第31章 南美洲市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第35章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 乳癌诊断市场：竞合情势と市场シェア、2024年
  • 乳癌诊断市场：公司估值矩阵
  • 乳癌诊断市场：企业プロファイル
    • Abbott Laboratories
    • Myriad Genetics Inc.
    • Hologic Inc.
    • Koninklijke Philips NV
    • Fujifilm Holdings Corporation

第37章：其他领先和创新企业

  • GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc.

第38章 全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年乳癌诊断市场：提供新机会的国家
  • 乳癌诊断市场2030年：新たな机会を提供するセグメント
  • 2030年乳癌诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第41章附录

简介目录
Product Code: ME4MBCDA04_G26Q1

Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.

Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.

Tariffs are impacting the breast cancer diagnostics market by increasing costs of imported imaging systems, genomic testing kits, reagents, biopsy devices, and advanced laboratory equipment. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported high-value diagnostic technologies, while Asia-Pacific faces cost pressures on equipment procurement and test consumables. These tariffs are raising operational costs and slowing technology upgrades in some healthcare facilities. However, they are also encouraging local manufacturing of diagnostic kits, regional reagent production, and domestic innovation in imaging and molecular testing solutions.

The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $5 billion in 2025 to $5.42 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising incidence of breast cancer globally, increased awareness of early cancer screening, expansion of diagnostic imaging infrastructure, growing availability of biomarker-based tests, improvements in biopsy accuracy and safety.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in AI-enabled diagnostic platforms, growing demand for minimally invasive testing, expansion of population-based screening programs, continuous advancements in molecular diagnostic technologies. Major trends in the forecast period include increasing adoption of ai-assisted imaging analysis, rising use of genomic and molecular testing, growing deployment of liquid biopsy techniques, expansion of advanced non-ionizing imaging modalities, enhanced focus on early and personalized diagnosis.

Government initiatives and funding for breast cancer are expected to drive growth in the breast cancer diagnostics market in the coming years. Such initiatives provide financial support to programs or projects that contribute to public health and economic development. These efforts play a crucial role in supporting breast cancer research, prevention, and treatment by raising awareness, promoting early detection through screening and mammography, and offering financial assistance to underserved communities for testing and treatment. For example, in its 2022-23 budget, the Australian Government Department of Health allocated $40.7 million to improve accessibility to testing and screening services for various cancers, addressing setbacks caused by the COVID-19 pandemic, and enabling timely referrals, prompt diagnosis, and early intervention. Of this, $9.7 million was specifically dedicated to breast cancer screening. Therefore, government initiatives and funding are supporting the expansion of the breast cancer diagnostics market.

Major companies operating in the breast cancer diagnostics market are focusing on AI-driven innovations to improve diagnostic accuracy, streamline workflows, and support personalized treatment planning. AI-based diagnostic platforms use machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, providing insights and risk stratifications that aid clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, expanded its AI platform for breast cancer diagnostics by introducing a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature in its Ibex Breast HER2 module. This tool identifies invasive cancer regions, classifies HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment decisions with enhanced accuracy and workflow efficiency.

In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition strengthens Hologic's breast surgery portfolio by integrating Endomag's wireless localization and lymphatic tracing solutions. Endomagnetics Ltd., based in the UK, provides advanced technologies for breast cancer diagnostics, including tissue localization and lymphatic mapping solutions.

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the breast cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Other Types
  • 2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
  • 3) By Cancer Type: BRCA Breast Cancer; ER And PR Breast Cancer; HER 2 Breast Cancer; Triple-Negative Breast Cancer; Other Cancer Types
  • 4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
  • 5) By End Users: Hospitals And Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers
  • Subsegments:
  • 1) By Imaging: Mammography; Ultrasound Imaging; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Tomosynthesis
  • 2) By Biopsy: Needle Biopsy; Core Needle Biopsy; Fine Needle Aspiration Biopsy (FNA); Stereotactic Biopsy
  • 3) By Genomic Tests: Oncotype DX; MammaPrint; PAM50; BRCA1 Or 2 Testing
  • 4) By Blood Tests: Liquid Biopsy; Circulating Tumor DNA (ctDNA) Tests; Circulating Tumor Cells (CTCs) Tests
  • 5) By Other Types: Hormone Receptor Tests; HER2 Tests; Genetic Mutation Testing
  • Companies Mentioned: Abbott Laboratories; Myriad Genetics Inc.; Hologic Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation; GE Healthcare; Thermo Fisher Scientific Inc.; Siemens AG; NanoString Technologies Inc.; Gamma Medica Inc.; Aurora Imaging Technology Inc.; Dilon Technologies Inc.; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd.; Micrima Limited; Provista Diagnostics Inc.; Leica Biosystems Nussloch GmbH; bioTheranostics Inc.; Bio-Rad Laboratories Inc.; Illumina Inc.; Biocept Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Cepheid; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Oncocyte Corporation; PerkinElmer Inc.; Sysmex Corporation; Veracyte Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Breast Cancer Diagnostics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Breast Cancer Diagnostics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Breast Cancer Diagnostics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Breast Cancer Diagnostics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Artificial Intelligence & Autonomous Intelligence
    • 4.1.2 Biotechnology, Genomics & Precision Medicine
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
    • 4.1.5 Industry 4.0 & Intelligent Manufacturing
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Ai-Assisted Imaging Analysis
    • 4.2.2 Rising Use Of Genomic And Molecular Testing
    • 4.2.3 Growing Deployment Of Liquid Biopsy Techniques
    • 4.2.4 Expansion Of Advanced Non-Ionizing Imaging Modalities
    • 4.2.5 Enhanced Focus On Early And Personalized Diagnosis

5. Breast Cancer Diagnostics Market Analysis Of End Use Industries

  • 5.1 Hospitals And Clinics
  • 5.2 Diagnostic Laboratories
  • 5.3 Cancer Research Centers
  • 5.4 Ambulatory Surgical Centers
  • 5.5 Specialty Oncology Clinics

6. Breast Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Breast Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Breast Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Breast Cancer Diagnostics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Breast Cancer Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Breast Cancer Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Breast Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Breast Cancer Diagnostics Market Segmentation

  • 9.1. Global Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types
  • 9.2. Global Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies
  • 9.3. Global Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types
  • 9.4. Global Breast Cancer Diagnostics Market, Segmentation By Diagnostic Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies
  • 9.5. Global Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers
  • 9.6. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Imaging, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis
  • 9.7. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Biopsy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy
  • 9.8. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Genomic Tests, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing
  • 9.9. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Blood Tests, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests
  • 9.10. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

10. Breast Cancer Diagnostics Market Regional And Country Analysis

  • 10.1. Global Breast Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Breast Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Breast Cancer Diagnostics Market

  • 11.1. Asia-Pacific Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Breast Cancer Diagnostics Market

  • 12.1. China Breast Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Breast Cancer Diagnostics Market

  • 13.1. India Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Breast Cancer Diagnostics Market

  • 14.1. Japan Breast Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Breast Cancer Diagnostics Market

  • 15.1. Australia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Breast Cancer Diagnostics Market

  • 16.1. Indonesia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Breast Cancer Diagnostics Market

  • 17.1. South Korea Breast Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Breast Cancer Diagnostics Market

  • 18.1. Taiwan Breast Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Breast Cancer Diagnostics Market

  • 19.1. South East Asia Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Breast Cancer Diagnostics Market

  • 20.1. Western Europe Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Breast Cancer Diagnostics Market

  • 21.1. UK Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Breast Cancer Diagnostics Market

  • 22.1. Germany Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Breast Cancer Diagnostics Market

  • 23.1. France Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Breast Cancer Diagnostics Market

  • 24.1. Italy Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Breast Cancer Diagnostics Market

  • 25.1. Spain Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Breast Cancer Diagnostics Market

  • 26.1. Eastern Europe Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Breast Cancer Diagnostics Market

  • 27.1. Russia Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Breast Cancer Diagnostics Market

  • 28.1. North America Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Breast Cancer Diagnostics Market

  • 29.1. USA Breast Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Breast Cancer Diagnostics Market

  • 30.1. Canada Breast Cancer Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Breast Cancer Diagnostics Market

  • 31.1. South America Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Breast Cancer Diagnostics Market

  • 32.1. Brazil Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Breast Cancer Diagnostics Market

  • 33.1. Middle East Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Breast Cancer Diagnostics Market

  • 34.1. Africa Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Breast Cancer Diagnostics Market, Segmentation By Type, Segmentation By Technology, Segmentation By Cancer Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Breast Cancer Diagnostics Market Regulatory and Investment Landscape

36. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 36.1. Breast Cancer Diagnostics Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Breast Cancer Diagnostics Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Breast Cancer Diagnostics Market Company Profiles
    • 36.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

37. Breast Cancer Diagnostics Market Other Major And Innovative Companies

  • GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc.

38. Global Breast Cancer Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Breast Cancer Diagnostics Market

40. Breast Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 40.1 Breast Cancer Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Breast Cancer Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Breast Cancer Diagnostics Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer